About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01286987

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Study identifier: NCT01286987
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

BMN 673 (BioMarin)

Eligibility:

  • Histologically or cytologically documented, unresectable, locally advanced or metastatic solid tumor
  • Have measurable disease or increased CA-125

Type of study:

Phase I/II

Treatment:

  • Patients receive BMN 673 orally once daily. Phase I will be a dose escalation study to determine the ideal dose for Phase II.

Study sites:

Arizona
TGen Clinical Research Services
Scottsdale, Arizona, 95258
Kelli Petersen 415-506-6700 kpetersen@bmrn.com

United Kingdom
Royal Marsden Hospital
Sutton, United Kingdom, SM2 5PT
Kelli Petersen 415-506-6700 kpetersen@bmrn.com

Page updated 08/31/11


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org